Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational

In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS. In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.

Participation Requirements
Sex: All
Minimum Age: Newborn
Maximum Age: 1 day

• Eligibility requirements for neonates were as follows:

• The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth

• The neonates will be diagnosed with NRDS or NARDS

• The neonates will be at least administrated one dose of surfactant

Other Locations
Contact Information
Chen Long, MD, PhD
Time Frame
Start Date: January 1, 2021
Estimated Completion Date: December 31, 2023
Target number of participants: 400
one dose of surfactant
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
two and more doses of surfactant
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Collaborators: Children's Hospital of Chongqing Medical University
Leads: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

This content was sourced from

Similar Clinical Trials